Novel therapies for Duchenne muscular dystrophy

Lancet Neurology

Volumn 2, Issue 5, 2003, Pages 299-310

  Kapsa, Robert ^a,b,c,d   Kornberg, Andrew J ^a,b,c,e   Byrne, Edward ^c,d  

^a Melbourne Neuromuscular Res Inst   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e Royal Childrens Hosptial ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; DYSTROPHIN; GENTAMICIN; PROTEIN DERIVATIVE; RECOMBINANT CYTOKINE; RECOMBINANT PROTEIN; UTROPHIN; VIRUS VECTOR;

CARBOXY TERMINAL SEQUENCE; CELL TRANSPLANTATION; DUCHENNE MUSCULAR DYSTROPHY; DYSTROPHIN GENE; ELECTROPORATION; EXON; EXPERIMENTAL MODEL; GENE; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; MOLECULAR MECHANICS; MUSCLE CELL; MUSCLE DISEASE; NONHUMAN; PATHOGENESIS; PLASMID; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SEQUENCE HOMOLOGY; STEM CELL TRANSPLANTATION; TECHNIQUE; TRANSGENE; TRANSLATION INITIATION; TREATMENT PLANNING; BIOLOGICAL THERAPY; GENE CONVERSION; GENE TRANSFER; GENE VECTOR; GENETICS; PATHOLOGY;

DYSTROPHIN; GENE CONVERSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; TISSUE THERAPY;

EID: 0042011472     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00382-X     Document Type: Review

References (148)

1. Watkins S.C., Hoffman E.P., Slayter H.S., Kunkel L.M. Immunoelectron microscopic localization of dystrophin in myofibres. Nature. 333:1988;863-866.
2. Ohlendieck K., Campbell K.P. Dystrophin constitutes 5% of membrane cytoskeleton in skeletal muscle. FEBS Lett. 283:1991;230-234.
3. Hoffman E.P., Brown R.H. Jr, Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 51:1987;919-928.
4. Koenig M., Monaco A.P., Kunkel L.M. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell. 53:1988;219-226.
5. Ohlendieck K., Campbell K.P. Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. J Cell Biol. 115:1991;1685-1694.
6. Ohlendieck K., Matsumura K., Ionasescu V.V., et al. Duchenne muscular dystrophy: deficiency of dystrophin-associated proteins in the sarcolemma. Neurology. 43:1993;795-800.
7. Hoffman E.P., Fischbeck K.H., Brown R.H., et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med. 318:1988;1363-1368.
8. Blau H.M., Webster C., Pavlath G.K. Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci USA. 80:1983;4856-4860.
9. Koenig M., Hoffman E.P., Bertelson C.J., Monaco A.P., Feener C., Kunkel L.M. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 50:1987;509-517.
10. Hoffman E.P., Monaco A.P., Feener C.C., Kunkel L.M. Conservation of the Duchenne muscular dystrophy gene in mice and humans. Science. 238:1987;347-350.
11. Monaco A.P., Bertelson C.J., Colletti-Feener C., Kunkel L.M. Localization and cloning of Xp21 deletion breakpoints involved in muscular dystrophy. HumGenet. 75:1987;221-227.
12. Nobile C., Marchi J., Nigro V., Roberts R.G., Danieli G.A. Exon-intron organization of the human dystrophin gene. Genomics. 45:1997;421-424.
13. Bies R.D., Phelps S.F., Cortez M.D., Roberts R., Caskey C.T., Chamberlain J.S. Human and murine dystrophin mRNA transcripts are differentially expressed during skeletal muscle, heart, and brain development. Nucleic Acids Res. 20:1992;1725-1731.
14. Boyce F.M., Beggs A.H., Feener C., Kunkel L.M. Dystrophin is transcribed in brain from a distant upstream promoter. Proc Natl Acad Sci USA. 88:1991;1276-1280.
15. Gorecki D.C., Monaco A.P., Derry J.M., Walker A.P., Barnard E.A., Barnard P.J. Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters. Hum Mol Genet. 1:1992;505-510.
16. Lederfein D., Levy Z., Augier N., et al. A 71-kilodalton protein is a major product of the Duchenne muscular dystrophy gene in brain and other nonmuscle tissues. Proc Natl Acad Sci USA. 89:1992;5346-5350.
17. D'Souza V.N., Nguyen T.M., Morris G.E., Karges W., Pillers D.A., Ray P.N. A novel dystrophin isoform is required for normal retinal electrophysiology. Hum Mol Genet. 4:1995;837-842.
18. Lidov H.G., Selig S., Kunkel L.M. Dp140: a novel 140 kDa CNS transcript from the dystrophin locus. Hum Mol Genet. 4:1995;329-335.
19. Blake D.J., Love D.R., Tinsley J., et al. Characterization of a 4.8kb transcript from the Duchenne muscular dystrophy locus expressed in Schwannoma cells. Hum Mol Genet. 1:1992;103-109.
20. Lidov H.G., Kunkel L.M. Dp140: alternatively spliced isoforms in brain and kidney. Genomics. 45:1997;132-139.
21. Hoffman E.P. Dystrophinopathies. Karpati G., Hilton-Jones D., Griggs R.C. Disorders of voluntary muscle. 7th edition :2001;385-432 Cambridge University Press, Cambridge.
22. Bulfield G., Siller W.G., Wight P.A., Moore K.J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA. 81:1984;1189-1192.
23. Cooper B.J., Winand N.J., Stedman H., et al. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature. 334:1988;154-156.
24. Carpenter J.L., Hoffman E.P., Romanul F.C., et al. Feline muscular dystrophy with dystrophin deficiency. Am J Pathol. 135:1989;909-919.
25. Im W.B., Phelps S.F., Copen E.H., Adams E.G., Slightom J.L., Chamberlain J.S. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet. 5:1996;1149-1153.
26. Sicinski P., Geng Y., Ryder-Cook A.S., Barnard E.A., Darlison M.G., Barnard P.J. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 244:1989;1578-1580.
27. Cox G.A., Cole N.M., Matsumura K., et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature. 364:1993;725-729.
28. Lynch G.S., Rafael J.A., Chamberlain J.S., Faulkner J.A. Contraction-induced injury to single permeabilized muscle fibres from mdx, transgenic mdx, and control mice. Am J Physiol Cell Physiol. 279:2000;C1290-C1294.
29. Phelps S.F., Hauser M.A., Cole N.M., et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet. 4:1995;1251-1258.
30. Chamberlain J.S. Dystrophin levels required for genetic correction of Duchenne muscular dystrophy. Basic Appl Myol. 7:1997;251-256.
31. England S.B., Nicholson L.V., Johnson M.A., et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 343:1990;180-182.
32. Jung D., Yang B., Meyer J., Chamberlain J.S., Campbell K.P. Identification and characterization of the dystrophin anchoring site on beta-dystroglycan. J Biol Chem. 270:1995;27305-27310.
33. Cox G.A., Sunada Y., Campbell K.P., Chamberlain J.S. Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nat Genet. 8:1994;333-339.
34. Warner L.E., DelloRusso C., Crawford R.W., et al. Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy. Hum Mol Genet. 11:2002;1095-1105.
35. Corrado K., Mills P.L., Chamberlain J.S. Deletion analysis of the dystrophin-actin binding domain. FEBS Lett. 344:1994;255-260.
36. Sakamoto M., Yuasa K., Yoshimura M., et al. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun. 293:2002;1265-1272.
37. Decrouy A., Renaud J.M., Lunde J.A., Dickson G., Jasmin B.J. Mini- and full-length dystrophin gene transfer induces the recovery of nitric oxide synthase at the sarcolemma of mdx 4cv skeletal muscle fibres. Gene Ther. 5:1998;59-64.
38. Wehling M., Spencer M.J., Tidball J.G. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol. 155:2001;123-131.
39. Acsadi G., Lochmuller H., Jani A., et al. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther. 7:1996;129-140.
40. Hauser M.A., Robinson A., Hartigan-O'Connor D., et al. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol Ther. 2:2000;16-25.
41. Hartigan-O'Connor D., Kirk C.J., Crawford R., Mule J.J., Chamberlain J.S. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther. 4:2001;525-533.
42. Acsadi G., Dickson G., Love D.R., et al. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature. 352:1991;815-818.
43. Danko I., Fritz J.D., Latendresse J.S., Herweijer H., Schultz E., Wolff J.A. Dystrophin expression improves myofibre survival in mdx muscle following intramuscular plasmid DNA injection. Hum Mol Genet. 2:1993;2055-2061.
44. Fritz J.D., Danko I., Roberds S.L., Campbell K.P., Latendresse J.S., Wolff J.A. Expression of deletion-containing dystrophins in mdx muscle: implications for gene therapy and dystrophin function. Pediatr Res. 37:1995;693-700.
45. McCarter G.C., Denetclaw W.F. Jr, Reddy P., Steinhardt R.A. Lipofection of a cDNA plasmid containing the dystrophin gene lowers intracellular free calcium and calcium leak channel activity in mdx myotubes. Gene Ther. 4:1997;483-487.
46. Braun S., Thioudellet C., Rodriguez P., et al. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice. Gene Ther. 7:2000;1447-1457.
47. Mir L.M., Bureau M.F., Gehl J., et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA. 96:1999;4262-4267.
48. Vilquin J.T., Kennel P.F., Paturneau-Jouas M., et al. Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies. Gene Ther. 8:2001;1097-1107.
49. Liu F., Nishikawa M., Clemens P.R., Huang L. Transfer of full-length dmd to the diaphragm muscle of dmd (mdx/mdx) mice through systemic administration of plasmid DNA. Mol Ther. 4:2001;45-51.
50. Romero N., Benveniste O., Payan C., et al. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies: part II, clinical protocol. Neuromuscul Disord. 12:(suppl):2002;S45-S48.
51. Thioudellet C., Blot S., Squiban S., Squiban P., Fardeau M., Braun S. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies: part I, rationale. Neuromuscul Disord. 12:(suppl):2002;S49-S51.
52. Fardeau M. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies: part III, ethical considerations. Neuromuscul Disord. 12:(suppl):2002;S52-S54.
53. Vincent N., Ragot T., Gilgenkrantz H., et al. Long-term correction of mouse dystrophic degeneration by adenovirus- mediated transfer of a minidystrophin gene. Nat Genet. 5:1993;130-134.
54. Acsadi G., Jani A., Massie B., et al. A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Hum Mol Genet. 3:1994;579-584.
55. Huard J., Feero W.G., Watkins S.C., Hoffman E.P., Rosenblatt D.J., Glorioso J.C. The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibres. J Virol. 70:1996;8117-8123.
56. Huang S., Endo R.I., Nemerow G.R. Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol. 69:1995;2257-2263.
57. Bouri K., Feero W.G., Myerburg M.M., et al. Polylysine modification of adenoviral fibre protein enhances muscle cell transduction. Hum Gene Ther. 10:1999;1633-1640.
58. Wickham T.J., Segal D.M., Roelvink P.W., et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol. 70:1996;6831-6838.
59. Huard J., Acsadi G., Jani A., Massie B., Karpati G. Gene transfer into skeletal muscles by isogenic myoblasts. Hum Gene Ther. 5:1994;949-958.
60. Danko I., Williams P., Herweijer H., et al. High expression of naked plasmid DNA in muscles of young rodents. Hum Mol Genet. 6:1997;1435-1443.
61. Russell W.C. Update on adenovirus and its vectors. J Gen Virol. 81:2000;2573-2604.
62. Amalfitano A., Hauser M.A., Hu H., Serra D., Begy C.R., Chamberlain J.S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol. 72:1998;926-933.
63. Clemens P.R., Kochanek S., Sunada Y., et al. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 3:1996;965-972.
64. DelloRusso C., Scott J.M., Hartigan-O'Connor D., et al. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl Acad Sci USA. 99:2002;12979-12984.
65. Kotin R.M., Siniscalco M., Samulski R.J., et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA. 87:1990;2211-2215.
66. Xiao X., Li J., Samulski R.J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 70:1996;8098-8108.
67. Hermonat P.L., Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA. 81:1984;6466-6470.
68. Dong J.Y., Fan P.D., Frizzell R.A. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther. 7:1996;2101-2112.
69. Yuasa K., Sakamoto M., Miyagoe-Suzuki Y., et al. Adeno-associated virus vector-mediated gene transfer into dystrophin- deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther. 9:2002;1576-1588.
70. Wang B., Li J., Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA. 97:2000;13714-13719.
71. Stedman H., Wilson J.M., Finke R., Kleckner A.L., Mendell J. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. Hum Gene Ther. 11:2000;777-790.
72. Li J., Dressman D., Tsao Y.P., Sakamoto A., Hoffman E.P., Xiao X. rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Ther. 6:1999;74-82.
73. Dunckley M.G., Wells D.J., Walsh F.S., Dickson G. Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo. Hum Mol Genet. 2:1993;717-723.
74. Fassati A., Wells D.J., Sgro Serpente P.A., et al. Genetic correction of dystrophin deficiency and skeletal muscle remodeling in adult MDX mouse via transplantation of retroviral producer cells. J Clin Invest. 100:1997;620-628.
75. Kafri T., Blomer U., Peterson D.A., Gage F.H., Verma I.M. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet. 17:1997;314-317.
76. Akkaraju G.R., Huard J., Hoffman E.P., et al. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. J Gene Med. 1:1999;280-289.
77. Tsukamoto H., Wells D., Brown S., et al. Enhanced expression of recombinant dystrophin following intramuscular injection of Epstein-Barr virus (EBV)-based mini-chromosome vectors in mdx mice. Gene Ther. 6:1999;1331-1335.
78. Roberts M.L., Athanasopoulos T., Pohlschmidt M., Duisit G., Cosset F.L., Dickson G. Post-mitotic, differentiated myotubes efficiently produce retroviral vector from hybrid adeno-retrovirus templates. Gene Ther. 8:2001;1580-1586.
79. Capecchi M.R. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell. 22:1980;479-488.
80. Mansour S.L., Thomas K.R., Deng C.X., Capecchi M.R. Introduction of a lacZ reporter gene into the mouse int-2 locus by homologous recombination. Proc Natl Acad Sci USA. 87:1990;7688-7692.
81. Thomas K.R., Capecchi M.R. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell. 51:1987;503-512.
82. Zimmer A., Gruss P. Production of chimaeric mice containing embryonic stem (ES) cells carrying a homoeobox Hox 1.1 allele mutated by homologous recombination. Nature. 338:1989;150-153.
83. Kunzelmann K., Legendre J.Y., Knoell D.L., Escobar L.C., Xu Z., Gruenert D.C. Gene targeting of CFTR DNA in CF epithelial cells. Gene Ther. 3:1996;859-867.
84. Goncz K.K., Kunzelmann K., Xu Z., Gruenert D.C. Targeted replacement of normal and mutant CFTR sequences in human airway epithelial cells using DNA fragments. Hum Mol Genet. 7:1998;1913-1919.
85. Dowty M.E., Williams P., Zhang G., Hagstrom J.E., Wolff J.A. Plasmid DNA entry into postmitotic nuclei of primary rat myotubes. Proc Natl Acad Sci USA. 92:1995;4572-4576.
86. Hagstrom J.E., Ludtke J.J., Bassik M.C., Sebestyen M.G., Adam S.A., Wolff J.A. Nuclear import of DNA in digitonin-permeabilized cells. J Cell Sci. 110:1997;2323-2331.
87. Kapsa R., Quigley A., Lynch G.S., et al. In vivo and in vitro correction of the mdx dystrophin gene nonsense mutation by short-fragment homologous replacement. Hum Gene Ther. 12:2001;629-642.
88. Kapsa R.M., Quigley A.F., Vadolas J., et al. Targeted gene correction in the mdx mouse using short DNA fragments: towards application with bone marrow-derived cells for autologous remodeling of dystrophic muscle. Gene Ther. 9:2002;695-699.
89. Kapsa R., Wong S., Bertoncello I., et al. CD45 fraction bone marrow cells as potential delivery vehicles for genetically corrected dystrophin loci. Neuromuscul Disord. 12:(Suppl):2002;S61.
90. Cole-Strauss A., Yoon K., Xiang Y., et al. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science. 273:1996;1386-1389.
91. Gamper H.B. Jr, Cole-Strauss A., Metz R., Parekh H., Kumar R., Kmiec E.B. A plausible mechanism for gene correction by chimeric oligonucleotides. Biochemistry. 39:2000;5808-5816.
92. Gamper H.B., Parekh H., Rice M.C., Bruner M., Youkey H., Kmiec E.B. The DNA strand of chimeric RNA/DNA oligonucleotides can direct gene repair/conversion activity in mammalian and plant cell-free extracts. Nucleic Acids Res. 28:2000;4332-4339.
93. Yoon K., Cole-Strauss A., Kmiec E.B. Targeted gene correction of episomal DNA in mammalian cells mediated by a chimeric RNA-DNA oligonucleotide. Proc Natl Acad Sci USA. 93:1996;2071-2076.
94. Kren B.T., Cole-Strauss A., Kmiec E.B., Steer C.J. Targeted nucleotide exchange in the alkaline phosphatase gene of HuH-7 cells mediated by a chimeric RNA/DNA oligonucleotide. Hepatology. 25:1997;1462-1468.
95. Rando T.A., Disatnik M.H., Zhou L.Z. Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. Proc Natl Acad Sci USA. 97:2000;5363-5368.
96. Bertoni C., Rando T.A. Dystrophin gene repair in mdx muscle precursor cells in vitro and in vivo mediated by RNA-DNA chimeric oligonucleotides. Hum Gene Ther. 13:2002;707-718.
97. Bartlett R.J., Stockinger S., Denis M.M., et al. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide. Nat Biotechnol. 18:2000;615-622.
98. Kren B.T., Parashar B., Bandyopadhyay P., Chowdhury N.R., Chowdhury J.R., Steer C.J. Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type I with a chimeric oligonucleotide. Proc Natl Acad Sci USA. 96:1999;10349-10354.
99. Dunckley M.G., Manoharan M., Villiet P., Eperon I.C., Dickson G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet. 7:1998;1083-1090.
100. Wilton S.D., Lloyd F., Carville K., et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord. 9:1999;330-338.
101. Mann C.J., Honeyman K., Cheng A.J., et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA. 98:2001;42-47.
102. van Deutekom J.C., Bremmer-Bout M., Janson A.A., et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 10:2001;1547-1554.
103. Barton-Davis E.R., Cordier L., Shoturma D.I., Leland S.E., Sweeney H.L. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest. 104:1999;375-381.
104. Howard M.T., Shirts B.H., Petros L.M., Flanigan K.M., Gesteland R.F., Atkins J.F. Sequence specificity of aminoglycoside-induced stop codon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol. 48:2000;164-169.
105. Wagner K.R., Hamed S., Hadley D.W., et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol. 49:2001;706-711.
106. Huard J., Roy R., Bouchard J.P., Malouin F., Richards C.L., Tremblay J.P. Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions. Transplant Proc. 24:1992;3049-3051.
107. Hodgetts S.I., Beilharz M.W., Scalzo A.A., Grounds M.D. Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or Nk1.1+ cells. Cell Transplant. 9:2000;489-502.
108. Gussoni E., Soneoka Y., Strickland C.D., et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature. 401:1999;390-394.
109. Partridge T.A., Grounds M., Sloper J.C. Evidence of fusion between host and donor myoblasts in skeletal muscle grafts. Nature. 273:1978;306-308.
110. Law P.K., Yap J.L. New muscle transplant method produces normal twitch tension in dystrophic muscle. Muscle Nerve. 2:1979;356-363.
111. Labrecque C., Roy R., Tremblay J.P. Immune reactions after myoblast transplantation in mouse muscles. Transplant Proc. 24:1992;2889-2892.
112. Tremblay J.P., Malouin F., Roy R., et al. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant. 2:1993;99-112.
113. Watt D.J., Morgan J.E., Partridge T.A. Long term survival of allografted muscle precursor cells following a limited period of treatment with cyclosporin A. Clin Exp Immunol. 55:1984;419-426.
114. Kinoshita I., Vilquin J.T., Guerette B., Asselin I., Roy R., Lille S., et al. Immunosuppression with FK 506 insures good success of myoblast transplantation in MDX mice. Transplant Proc. 26:1994;3518.
115. Mendell J.R., Kissel J.T., Amato A.A., et al. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med. 333:1995;832-838.
116. Partridge T., Lu Q.L., Morris G., Hoffman E. Is myoblast transplantation effective? Nat Med. 4:1998;1208-1209.
117. Rando T.A., Blau H.M. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol. 125:1994;1275-1287.
118. Rosenblatt J.D., Lunt A.I., Parry D.J., Partridge T.A. Culturing satellite cells from living single muscle fibre explants. In Vitro Cell Dev Biol Anim. 31:1995;773-779.
119. Jankowski R.J., Haluszczak C., Trucco M., Huard J. Flow cytometric characterization of myogenic cell populations obtained via the preplate technique: potential for rapid isolation of muscle-derived stem cells. Hum Gene Ther. 12:2001;619-628.
120. Beauchamp J.R., Heslop L., Yu D.S., et al. Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells. J Cell Biol. 151:2000;1221-1234.
121. Lee J.Y., Qu-Petersen Z., Cao B., et al. Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. J Cell Biol. 150:2000;1085-1100.
122. Beauchamp J.R., Morgan J.E., Pagel C.N., Partridge T.A. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J Cell Biol. 144:1999;1113-1122.
123. Jankowski R.J., Deasy B.M., Huard J. Muscle-derived stem cells. Gene Ther. 9:2002;642-647.
124. Torrente Y., Tremblay J.P., Pisati F., et al. Intraarterial injection of muscle-derived CD34(+)Sca-1(+) stem cells restores dystrophin in mdx mice. J Cell Biol. 152:2001;335-348.
125. Heslop L., Beauchamp J.R., Tajbakhsh S., Buckingham M.E., Partridge T.A., Zammit P.S. Transplanted primary neonatal myoblasts can give rise to functional satellite cells as identified using the Myf5nlacZl+ mouse. Gene Ther. 8:2001;778-783.
126. Heslop L., Morgan J.E., Partridge T.A. Evidence for a myogenic stem cell that is exhausted in dystrophic muscle. J Cell Sci. 113:2000;2299-2308.
127. Bittner R.E., Schofer C., Weipoltshammer K., et al. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat Embryol (Berl). 199:1999;391-396.
128. Ferrari G., Cusella-De Angelis G., Coletta M., et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science. 279:1998;1528-1530.
129. Malouf N.N., Coleman W.B., Grisham J.W., et al. Adult-derived stem cells from the liver become myocytes in the heart in vivo. Am J Pathol. 158:2001;1929-1935.
130. Zuk P.A., Zhu M., Mizuno H., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 7:2001;211-228.
131. Jiang Y., Vaessen B., Lenvik T., Blackstad M., Reyes M., Verfaillie C.M. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol. 30:2002;896-904.
132. Tinsley J.M., Davies K.E. Utrophin: a potential replacement for dystrophin? Neuromuscul Disord. 3:1993;537-539.
133. Burkin D.J., Wallace G.Q., Nicol K.J., Kaufman D.J., Kaufman S.J. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol. 152:2001;1207-1218.
134. Austin L., Bower J.J., Bennett T.M., et al. Leukemia inhibitory factor ameliorates muscle fibre degeneration in the mdx mouse. Muscle Nerve. 23:2000;1700-1705.
135. Gregorevic P., Plant D.R., Leeding K.S., Bach L.A., Lynch G.S. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am J Pathol. 161:2002;2263-2272.
136. Bogdanovich S., Krag T.O., Barton E.R., et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 420:2002;418-421.
137. Fischer M.D., Gorospe J.R., Felder E., et al. Expression profiling reveals metabolic and structural components of extraocular muscles. Physiol Genomics. 9:2002;71-84.
138. Ohlendieck K., Ervasti J.M., Matsumura K., Kahl S.D., Leveille C.J., Campbell K.P. Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle. Neuron. 7:1991;499-508.
139. Buckle V.J., Guenet J.L., Simon-Chazottes D., Love D.R., Davies K.E. Localisation of a dystrophin-related autosomal gene to 6q24 in man, and to mouse chromosome 10 in the region of the dystrophia muscularis (dy) locus. Hum Genet. 85:1990;324-326.
140. Nguyen T.M., Ellis J.M., Love D.R., et al. Localization of the DMDL gene-encoded dystrophin-related protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines. J Cell Biol. 115:1991;1695-1700.
141. Clerk A., Morris G.E., Dubowitz V., Davies K.E., Sewry C.A. Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle. Histochem J. 25:1993;554-561.
142. Deconinck A.E., Rafael J.A., Skinner J.A., et al. Utrophin-dystrophin- deficient mice as a model for Duchenne muscular dystrophy. Cell. 90:1997;717-727.
143. Tinsley J.M., Potter A.C., Phelps S.R., Fisher R., Trickett J.I., Davies K.E. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature. 384:1996;349-353.
144. Fujimori K., Itoh Y., Yamamoto K., et al. Interleukin 6 induces overexpression of the sarcolemmal utrophin in neonatal mdx skeletal muscle. Hum Gene Ther. 13:2002;509-518.
145. Chaubourt E., Fossier P., Baux G., Leprince C., Israel M., De La P.S. Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy. Neurobiol Dis. 6:1999;499-507.
146. Raper S.E., Yudkoff M., Chirmule N., et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther. 13:2002;163-175.
147. Cavazzana-Calvo M., Hacein-Bey S., de Saint B.G., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 288:2000;669-672.
148. Marshall E. Clinical research: gene therapy a suspect in leukemia-like disease. Science. 298:2002;34-35.